A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate if an investigational drug called AT13387 is
active against Gastrointestinal Stromal Tumor (GIST) that is resistant to other treatments,
and to understand more about the safety of AT13387.
Most subjects in the study will receive AT13387 along with another drug called imatinib
(Gleevec). Imatinib is a standard (approved) drug for treating patients with GIST. Some
patients may receive AT13387 on its own. As a result, we shall begin to understand the
effects of AT13387 given on its own and when combined with imatinib.We shall also find out
more about the side-effects of AT13387, and more about how the body breaks down (metabolizes)
AT13387.